Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.435 USD | -3.75% | -5.45% | +37.29% |
Financials (USD)
Sales 2024 * | 9.22M | Sales 2025 * | 5.09M | Capitalization | 473M |
---|---|---|---|---|---|
Net income 2024 * | -77M | Net income 2025 * | -92M | EV / Sales 2024 * | 40.2 x |
Net cash position 2024 * | 102M | Net cash position 2025 * | 144M | EV / Sales 2025 * | 64.7 x |
P/E ratio 2024 * |
-6.23
x | P/E ratio 2025 * |
-5.32
x | Employees | 52 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.53% |
Latest transcript on Taysha Gene Therapies, Inc.
1 day | +6.30% | ||
1 week | -1.94% | ||
Current month | +4.12% | ||
1 month | -14.53% | ||
3 months | +50.60% | ||
6 months | +44.57% | ||
Current year | +42.94% |
Managers | Title | Age | Since |
---|---|---|---|
Sean Nolan
CEO | Chief Executive Officer | 56 | 20-02-29 |
Kamran Alam
DFI | Director of Finance/CFO | 46 | 20-07-31 |
President | 58 | 20-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Philip Donenberg
BRD | Director/Board Member | 63 | 20-08-30 |
Sean Nolan
CEO | Chief Executive Officer | 56 | 20-02-29 |
Sean Stalfort
BRD | Director/Board Member | 54 | 23-06-20 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 2.43 | -3.95% | 244 048 |
24-05-09 | 2.53 | +6.30% | 1,236,896 |
24-05-08 | 2.38 | -4.03% | 1,850,885 |
24-05-07 | 2.48 | -5.34% | 1,384,000 |
24-05-06 | 2.62 | +1.95% | 860,439 |
Delayed Quote Nasdaq, May 09, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+42.94% | 473M | |
+23.37% | 47.02B | |
+49.84% | 41.86B | |
-0.94% | 41.76B | |
-4.32% | 28.8B | |
+11.29% | 26.05B | |
-20.92% | 19.15B | |
+3.20% | 12.55B | |
-2.67% | 11.82B | |
+30.23% | 12.34B |
- Stock Market
- Equities
- TSHA Stock